In vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Yang, Lei ^a   You, Shuo ^b   Kumar, Vikas ^c   Zhang, Chaoyue ^a   Cao, Ya ^d  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d Central South University   (China)

Author keywords

Bone; Metastasis; Prostate cancer; VEGF

Indexed keywords

BEVACIZUMAB; FIBROBLAST GROWTH FACTOR 2; IMMUNOGLOBULIN G; INTERLEUKIN 8; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL STRAIN LNCAP; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL, HUMANIZED; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MALE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862182814     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-40     Document Type: Article

References (25)

1. Dormancy of metastatic melanoma. Ossowski L, Aguirre-Ghiso JA, Pigment Cell Melanoma Res 2010 23 41 65 10.1111/j.1755-148X.2009.00647.x 19843243
2. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ, Nat Med 2000 6 100 102 10.1038/71429 10613833 (Pubitemid 30048535)
3. Correlation of matrix metalloproteinases and their inhibitors with hypoxia and angiogenesis in premenopausal patients with adenocarcinoma of the breast. Vinothini G, Aravindraja C, Chitrathara K, Nagini S, ClinBiochem 2011 44 969 74
4. Regulation of VEGF, MMP-9 and metastasis by CXCR4 in a prostate cancer cell line. Wang Q, Diao X, Sun J, Chen Z, Cell Biology International 2011 35 897 904 10.1042/CBI20100744 21306303
5. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer. Quaranta M, Daniele A, Coviello M, Venneri MT, Abbate I, Caringella ME, Di Tardo S, Divella R, Trerotoli P, Di Gennaro M, Schittulli F, Fransvea E, Giannelli G, Anticancer. Res. 2007 27 3693 600 17970030
6. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Bubendorf L, Schopfer A, Wangner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ, Hum. Pathol. 2000 31 578 583 10.1053/hp.2000.6698 10836297 (Pubitemid 30323983)
7. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL, J. Urol. 1997 157 6 2329 33 10.1016/S0022-5347(01)64775-X 9146665 (Pubitemid 27208716)
8. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL, Urology 1998 51 1 161 7 10.1016/S0090-4295(97)00491-3 9610574 (Pubitemid 28092530)
9. Expression of vascular endothelial growth factor receptors in human prostate cancer. Ferrer FA, Miller LJ, Lindquist R, Kowalczyk P, Laudone VP, Albertsen PC, Kreutzer DL, Urology 1999 54 3 567 72 10.1016/S0090-4295(99)00156- 9 10475375 (Pubitemid 29407042)
10. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J, Am. J. Pathol. 1993 143 2 401 9 7688183 (Pubitemid 24058195)
11. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N, Nat Med 1999 5 6 623 8 10.1038/9467 10371499 (Pubitemid 29289424)
12. Bevacizumab in metastatic breast cancer: when may it be used? ldfarb SB, Hudis C, Dickler MN, Ther Adv Med Oncol 2011 3 2 85 93 21789158
13. Bevacizumab in non-small cell lung cancer. Di Costanzo F, Mazzoni F, Micol Mela M, Antonuzzo L, Checcacci D, Saggese M, Di Costanzo F, Drugs 2008 68 6 737 46 10.2165/00003495-200868060-00002 18416583 (Pubitemid 351550528)
14. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. deGramont A, Van Cutsem E, Oncology 2005 69 suppl 3 46 56 16301835 (Pubitemid 41680952)
15. Intravitreal bevacizumab (Avastin) for choroidal metastasis secondary to breast carcinoma: short-term follow-up. Amselem L, Cervera E, Díaz-Llopis M, Montero J, Garcia-Pous M, Udaondo P, García-Delpech S, Salom D, Eye 2007 21 4 566 567 17128202 (Pubitemid 46564160)
16. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Zondor SD, Medina PJ, Ann. Pharmacother. 2004 38 7-8 1258 1264 15187215 (Pubitemid 38802172)
17. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-2) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Brekken R, Overholser J, Stastny V, Waltenberger J, Minna JD, Thorpe PE, Cancer Res. 2000 60 18 5117 5124 11016638
18. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Yang H, Jager MJ, Grossniklaus HE, Invest Ophthalmol Vis Sci 2010 51 6 2835 42 10.1167/iovs.09-4755 20089875
19. A monoclonal antibody that blocks VEGF binding to VEGFR2 (KDR/Flk-1) inhibits vascular expression of Flk-1 and tumor growth in an orthotopic human breast cancer model. Zhang W, Ran S, Sambade M, Huang X, Thorpe PE, Angiogenesis 2002 5 1-2 35 44 12549858 (Pubitemid 36076921)
20. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG, Br. J. Ophthalmol. 2000 84 7 750 756 10.1136/bjo.84.7.750 10873988 (Pubitemid 30438555)
21. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouringuveal melanoma: identification of a potential therapeutic window. Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA, Br. J. Ophthalmol. 2002 86 4 448 452 10.1136/bjo.86.4.448 11914216 (Pubitemid 34293296)
22. Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. Crosby MB, Yang H, Gao W, Zhang L, Grossniklaus HE, Br. J. Ophthalmol. 2011 95 1 112 7 10.1136/bjo.2010.182402 20819828
23. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Shweiki D, Itin A, Soffer D, Keshet E, Nature 1992 359 6398 843 845 10.1038/359843a0 1279431
24. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Claffey KP, Robinson GS, Cancer Metastasis Rev. 1996 15 2 165 176 10.1007/BF00437469 8842488 (Pubitemid 26236114)
25. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Gerber HP, Ferrara N, Cancer Res. 2005 65 3 671 680 15705858 (Pubitemid 40216420)